Aim: To assess predictors of alanine aminotransferase (ALT) elevation in methotrexate (MTX) treated rheumatoid arthritis (RA) patients, and to describe the monitoring of liver enzymes, including handling and outcome of elevated ALT.
| INTRODUC TI ON
Since the introduction of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in the 1980s, the risk for hepatic complications has been a major concern. 1 which may be due to differences in the studied populations regarding, for example sex distribution, age, MTX dosing, and the use of folic acid supplementation. [5] [6] [7] [8] In this study we aimed to assess predictors of ALT elevation in a contemporary and unselected population of MTX-treated RA patients and to describe monitoring of liver enzymes in long-term follow-up in clinical practice, including compliance to guidelines and the handling and outcome of elevated ALT levels.
| MATERIAL S AND ME THODS

| Study population
We performed a retrospective cohort study of all RA patients at the Rheumatology Department at Uppsala University Hospital, Sweden, who started MTX treatment between 1 January, 2005 and 30 April, 2013. Patients were identified from electronic medical records (n = 232) and asked to participate in the study, which also included a telephone interview. Sixteen patients declined participation and three were excluded since they were not able to take part in the telephone interview (severe dementia or communication problems), resulting in a total of 213 included patients.
At initiation of MTX, all patients were prescribed 7.5 mg/wk orally in combination with folic acid (at least 5 mg/wk, not the same day as MTX), according to Swedish guidelines The dose of MTX was gradually increased during a period of 1-3 months to a maximum of 25 mg/wk based on individual decisions by the treating physician.
Patients were scheduled to perform ALT tests according to Swedish guidelines, that is every 14 days during the first 3 months of MTX treatment, thereafter every month for 3 months, followed by tests every 3 months as long as MTX treatment was maintained. The guidelines concerning MTX treatment were stable during the study period.
Ethics approval was obtained from the Regional Ethical Review Board, Uppsala, Sweden (Uppsala 2010/231). All participating patients were required to be at least 18 years of age and able to provide written informed consent. 
| Clinical and laboratory data and follow-up
| Statistical analysis
| RE SULTS
The study comprised of 213 RA patients (67% women) starting Table 1 .
| Results of ALT testing and compliance to guidelines
During the study period, 6288 ALT tests were performed, corre- (88%) within the first 3 years after treatment start (Tables 2 and 3 ).
Compliance to scheduled blood tests was lowest the first year after treatment start. On average 63% of the patients followed the recommendations of the tighter controls during the first year, but compliance improved up to 82% during the next 2 years. An inferior compliance was noted in men compared to women (P = 0.004) and in those with a lower mean age at MTX start (52 vs 58 years, P = 0.001). There were no significant differences between those with compliance to testing guidelines and those with less frequent testing the first year regarding the proportion of patients with TA B L E 1 Characteristics of included patients 
| Predictors for elevated ALT after MTX initiation
The strongest predictor for ALT >1.5× ULN was a former known elevation of ALT > ULN recorded before onset of MTX therapy (adjusted OR = 6.8, 95% CI 2.2-20. (Table 4) .
No additional risk factors for ALT >2× and >3× ULN were detected, although statistical power was limited due to few patients in these groups (data not shown). 
| Interventions following elevated ALT
We compared the patients where the treating physician decided not to perform any intervention or only a new ALT test ahead of schedule at the first ALT elevation (n = 61) with those where an intervention (ie further laboratory or radiographic investigation, dose reduction or temporary interruption of MTX or of other concomitant potentially liver-toxic drugs) was performed (n = 21) (information missing We also noted a sex-related difference. Occurrence of any ALT elevation and a lower mean relative ALT increase more often led to interventions in men than in women. Thus, in men 54% of elevated ALT tests led to interventions compared to 37% in women (P = 0.002). The average increase of ALT leading to interventions in men was 1.6× ULN (1.76 µcat/L) and in women 2.0× ULN (1.50 µcat/L) (P = 0.003). We found no differences in characteristics between men and women that could explain this difference (data not shown).
We identified a group of patients whose ALT remained normal throughout the study after a spontaneous normalization of a first ALT elevation (n = 16). These patients had a lower mean ALT increase (1.2× ULN vs 1.6× ULN) (P = 0.003) and a longer mean time to the first elevation than the 68 with recurrent ALT elevations (148 vs 62 weeks) (P < 0.001). Other characteristics and follow-up times were similar in both groups.
| Patients with permanent cessation of MTX therapy
Among the seven patients who eventually permanently stopped MTX due to elevated ALT, 5 (71%) had continued ALT elevations after stopping MTX ( Table 6 ). The mean follow-up time after stopping MTX in the seven patients was 6.7 years (3.8-8.6 years). None of the patients in this study developed signs of hepatic failure.
| D ISCUSS I ON
In this study we have examined the incidence of ALT elevations and ALT, alanine aminotransferase; MTX, methotrexate; ULN, upper limit normal a One patient had persistent ALT elevation after stopping MTX and was later diagnosed with non-alcoholic fatty liver disease ALT > ULN, 22% ALT >1.5× ULN and 15% >2× ULN, figures coherent with prior studies. 6,7,9-11 Also similar to more recent studies of MTX toxicity, only a small proportion of the patients (3%) discontinued their MTX medication due to pathological ALT tests and no patients developed signs of severe liver toxicity. [4] [5] [6] Two of the patients were later investigated and diagnosed with NAFLD. It could be speculated that NAFLD could be a cause of recurrent ALT elevations in more of the patients, if they had been properly investigated. It is obvious that NAFDL and MTX-related liver toxicity share risk factors, which could support a common background for both conditions. NAFLD is linked to overweight and obesity, diabetes type 2, insulin resistance and hyperlipidemia. 15, 16 The disease is becoming increasingly common, especially in Western countries. A potentially serious form of NAFDL, non-alcoholic steatohepatitis (NASH), may progress to cirrhosis and liver failure. 15, 16 Primary treatment of NAFDL includes weight reduction and physical activity. 17 Apart from pre-treatment ALT elevation, we identified female 19 and seldom lead to a permanent discontinuation of MTX. 5, 20 Accordingly, in patients with small and late-occurring ALT elevations, an approach without interventions and frequent retesting seems reasonable.
Another finding was that a majority of patients with ALT elevations, approximately 70%, had recurrent elevations. Importantly, this
proportion was similar in patients in whom active interventions were performed and in those were only a new ALT test was ordered. These observations support the notion of a multifactorial background to the ALT elevations and the need to consider other factors than MTX as the cause of ALT elevations. It also supports that monitoring and interventions of liver toxicity may benefit from a more individualized approach than in the current guidelines.
Some strengths and limitations of the study should be discussed.
Strengths include the detailed, congruent clinical information from electronic medical records, additional information on BMI, alcohol intake and smoking habits on all patients through a telephone interview, access to all ALT values in a computerized database both before and after MTX start, and the long follow-up after first ALT elevation.
Limitations include that most of the clinical information was retrospectively collected and some relevant information may have been missing, for example the reasons for the pre-treatment ALT elevations could not be evaluated. There is also a potential risk for recall bias for data from the telephone interview. The observational design confers a risk for channeling bias. Patients with high risk for liver complications may have been prescribed other DMARDs than MTX, but still 87% of the patients received MTX as the first DMARD.
The observational design and the lack of a common routine also entail a variability in the time span to normalization of an ALT elevation which is dependent on the decisions of the individual doctor on how to handle an elevation and when to perform the next ALT test.
The group of patients under study is relatively small, especially for the predictor analysis.
In conclusion, this study emphasizes a multifactorial background to ALT elevations during MTX therapy, and pre-treatment ALT elevations as a strong predictor for early and recurrent ALT elevations following start of MTX. NAFDL is one possible underlying reason to consider pre-treatment and recurrent ALT elevations. During longterm follow-up, only a minority of all performed ALT tests captures elevations. The results suggest that it may be more efficient to find an individualized approach to monitoring of liver toxicity during MTX therapy in RA patients.
CO N FLI C T S O F I NTE R E S T
None. org/0000-0001-5313-7981
AUTH O R CO NTR
R E FE R E N C E S
